Lavrenko, A. V.Rasdin, M.Savchenko, L.Mamontova, T.Vesnina, L.Kaidashev, I.Кайдашев, Ігор ПетровичЛавренко, Анна ВолодимирівнаСавченко, Людмила ПетрівнаМамонтова, Тетяна ВасилівнаВесніна, Людмила Едуардівна2017-10-232017-10-232014Results of a 3 month treatment with Metformin in patients with type 2 diabetes mellitus associated with ischaemic heart disease / A. V. Lavrenko, M. S. Rasdin, L. G. Savchenko [et al.] // Проблеми екології та медицини. – 2014. – Т. 18, № 3–4. – С. 75–78.https://repository.pdmu.edu.ua/handle/123456789/1492MSEI of Ukraine «Ukrainian Medical Stomatological Academy«, Poltava the aim of the research was to investigate the effectiveness of mid-term inclusion of Metformin in the complex therapy in patients with diabetes type 2 in combination with IHD for the rational justification of timing, doses of the drug. Materials and methods. 52 man suffering from diabetes type 2 on background of ischaemic heart disease have been observed. An effect of included Metformin at mid-term rate (3 months) was estimated. The blood rates are observed (total cholesterol (TC), HDL-cholesterol, total lipids (TL), triglycerides (TG), β-lipoproteins, glycated hemoglobin, C-peptide) and anti inflammatory markers (IL-1β, IL-6, IL-8 and TNF-α). Results. In patients with diabetes type 2 on background of ischaemic heart disease during 3 months under the action of metformin significant decrease in body weight, waist circumference, BMI, concentration of total cholesterol, C-peptide and insulin resistance index and cytokines level IL-1β, IL-6 and TNF-α were observed. Conclusion. The obtained results indicate the purpose of Metformin prescription in patients with diabetes type 2 and IHD in the continuation of 3 months; it is an effective and safe method of treatment of such patients.entype 2diabetes mellitusischaemic heart diseaseinsulin resistancemetforminsystemic inflammationanginaArticle